LLC0424N 

LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia^[1].

LLC0424N (0.5-2 μM; 12-24 h) does not potently degrade NSD2 protein in SEM ALL cells^[1].
LLC0424N (2 μM; 8-24 h) does not downregulate NSD2 or H3K36me2 protein levels in SEM ALL and RPMI-8402 cells^[1].
LLC0424N (100 nM-30 μM; 7 days) does not dose-dependently inhibit the growth of SEM ALL and RPMI-8402 cells^[1].
LLC0424N (2 μM; 30 days ) does not reduce colony formation or size in RPMI-8402 ALL cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

837.88

C₄₆H₄₃N₇O₉

3063448-59-6

O=C(N1)COC2=C1C=CC(C(N(C3CC3)CC4=CC=C(C(NC5=CC=C(C(NC6CCN(C7=CC=C(C(N(C8C(N(C)C(CC8)=O)=O)C9=O)=O)C9=C7)CC6)=O)C=C5)=O)C=C4)=O)=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu L, et al. Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader[J]. Journal of Medicinal Chemistry, 2024, 67(9): 6938-6951.  [Content Brief]